Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 1NIH 1NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Endocrine 3Gastrointestinal 1

Conditions

Breast Neoplasms 387Colorectal Neoplasms 307Rectal Neoplasms 224Stomach Neoplasms 206Pancreatic Neoplasms 137Neoplasm Metastasis 121Colonic Neoplasms 93Neoplasms 85Triple Negative Breast Neoplasms 63Esophageal Neoplasms 57Biliary Tract Neoplasms 37Nasopharyngeal Carcinoma 36Adenocarcinoma 31Cholangiocarcinoma 30Carcinoma, Hepatocellular 30Gallbladder Neoplasms 28Carcinoma, Non-Small-Cell Lung 21Bile Duct Neoplasms 21Locally Advanced Rectal Cancer 20Adenocarcinoma Of Esophagus 20Squamous Cell Carcinoma of Head and Neck 19Gastrointestinal Neoplasms 18Brain Neoplasms 18Parkinson Disease 4, Autosomal Dominant Lewy Body 17Liver Neoplasms 17Head and Neck Neoplasms 17Esophageal Squamous Cell Carcinoma 17Ovarian Neoplasms 14Colorectal Cancer Metastatic 14Breast Neoplasms, Male 14

Interventions

Everolimus 5Octreotide 4Leucovorin 4Temozolomide 3Oxaliplatin 3Fluorouracil 3Capecitabine 3vatalanib 2temsirolimus 2Trastuzumab 2Sirolimus 2Melphalan 2Irinotecan 2Biological Therapy 2Bevacizumab 2tipifarnib 1romidepsin 1regorafenib 1pentetreotide 1pazopanib 1napabucasin 1motesanib diphosphate 1irinotecan sucrosofate 1folfirinox 1cixutumumab 1batifiban 1antineoplaston AS 2-1 1antineoplaston A10 1Vinorelbine 1Thalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Islet Cell × Capecitabine × Clear all
NCT01824875 2026-02-25

Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
144 enrolled 15 charts
Endocrine

Glucagonoma, Insulinoma, Adenoma, Islet Cell, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT01525082 2024-02-06

Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors

Stanford University

Phase 2 Completed
20 enrolled 15 charts
EndocrineGastrointestinal

Glucagonoma, Insulinoma, Pancreatic Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT00602082 2013-08-07

Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Completed
84 enrolled
Endocrine

Glucagonoma, Insulinoma, Adenoma, Islet Cell, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡